SUPERNUS PHARMACEUTICALS, INC. Interest Expense, Other
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Interest Expense, Other of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseOther · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for fiscal 2025 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for fiscal 2023 was $562.00K, a 76.74% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. interest expense, other for fiscal 2022 was $2.42M, a 35.18% decline from fiscal 2021.
| Period end | Interest Expense, Other 3 month | Interest Expense, Other 6 month | Interest Expense, Other 9 month | Interest Expense, Other 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $245.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $245.00K derived: sum of 3 quarters · filed 2026-03-02 | $562.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $245.00K derived: sum of 2 quarters · filed 2024-08-06 | $562.00K 10-Q · filed 2023-11-08 | $990.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $245.00K 10-Q · filed 2024-08-06 | $562.00K 10-Q · filed 2024-08-06 | $990.00K derived: sum of 3 quarters · filed 2025-02-25 | $1.56M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $317.00K 10-Q · filed 2024-05-08 | $745.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.31M derived: sum of 3 quarters · filed 2025-02-25 | $1.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $994.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.63M derived: sum of 3 quarters · filed 2025-02-25 | $2.42M 10-K · filed 2025-02-25 |
| 2022-09-30 | $566.00K 10-Q · filed 2023-11-08 | $1.20M derived: sum of 2 quarters · filed 2023-11-08 | $1.99M 10-Q · filed 2023-11-08 | $2.82M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $635.00K 10-Q · filed 2023-08-08 | $1.42M 10-Q · filed 2023-08-08 | $2.25M derived: sum of 3 quarters · filed 2023-08-08 | $3.15M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $787.00K 10-Q · filed 2023-05-09 | $1.62M derived: sum of 2 quarters · filed 2023-05-09 | $2.51M derived: sum of 3 quarters · filed 2023-05-09 | $3.48M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.72M derived: sum of 2 quarters · filed 2023-03-09 | $2.69M derived: sum of 3 quarters · filed 2023-03-09 | $3.73M 10-K · filed 2023-03-09 |
| 2021-09-30 | $892.00K 10-Q · filed 2022-11-09 | $1.86M derived: sum of 2 quarters · filed 2022-11-09 | $2.90M 10-Q · filed 2022-11-09 | $3.99M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $969.00K 10-Q · filed 2022-08-08 | $2.00M 10-Q · filed 2022-08-08 | $3.10M derived: sum of 3 quarters · filed 2023-03-09 | $4.24M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-12 | $2.13M derived: sum of 2 quarters · filed 2023-03-09 | $3.27M derived: sum of 3 quarters · filed 2023-03-09 | $4.29M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.23M derived: sum of 2 quarters · filed 2023-03-09 | $3.26M derived: sum of 3 quarters · filed 2023-03-09 | $4.32M 10-K · filed 2023-03-09 |
| 2020-09-30 | $1.14M 10-Q · filed 2021-11-05 | $2.17M derived: sum of 2 quarters · filed 2021-11-05 | $3.23M 10-Q · filed 2021-11-05 | $4.32M derived: sum of 4 quarters · filed 2022-04-13 |
| 2020-06-30 | $1.02M 10-Q · filed 2021-08-06 | $2.08M 10-Q · filed 2021-08-06 | $3.17M derived: sum of 3 quarters · filed 2022-04-13 | $4.29M derived: sum of 4 quarters · filed 2022-04-13 |
| 2020-03-31 | $1.06M 10-Q · filed 2021-05-07 | $2.15M derived: sum of 2 quarters · filed 2022-04-13 | $3.27M derived: sum of 3 quarters · filed 2022-04-13 | $4.40M derived: sum of 4 quarters · filed 2022-04-13 |
| 2019-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $2.20M derived: sum of 2 quarters · filed 2022-04-13 | $3.34M derived: sum of 3 quarters · filed 2022-04-13 | $4.50M 10-K · filed 2022-04-13 |
| 2019-09-30 | $1.12M 10-Q · filed 2020-11-06 | $2.25M derived: sum of 2 quarters · filed 2020-11-06 | $3.41M 10-Q · filed 2020-11-06 | $4.59M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $1.14M 10-Q · filed 2020-08-17 | $2.30M 10-Q · filed 2020-08-17 | $3.47M derived: sum of 3 quarters · filed 2021-03-08 | $4.66M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $1.16M 10-Q · filed 2020-05-15 | $2.33M derived: sum of 2 quarters · filed 2021-03-08 | $3.53M derived: sum of 3 quarters · filed 2021-03-08 | $4.73M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $2.37M derived: sum of 2 quarters · filed 2021-03-08 | $3.57M derived: sum of 3 quarters · filed 2021-03-08 | $4.27M 10-K · filed 2021-03-08 |
| 2018-09-30 | $1.19M 10-Q · filed 2019-11-08 | $2.40M derived: sum of 2 quarters · filed 2019-11-08 | $3.10M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $1.20M 10-Q · filed 2019-08-09 | $1.91M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $701.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $1.43M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |